Meilleure Health International Industry Group Limited (HK:2327)
:2327
Top Page
Meilleure Health International Industry Group Limited
(2327)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.25
▼(-11.43% Downside)
Action:ReiteratedDate:11/01/25
The overall stock score is primarily influenced by the company's mixed financial performance and technical indicators. The financial performance shows significant volatility, which poses a risk. Technical analysis indicates some short-term positive momentum but lacks strong directional signals. The valuation suggests the stock may be overvalued, further impacting the score.
Positive Factors
EPS Growth
Reported EPS growth of ~26% indicates the company has improved per-share profitability despite top-line pressures. Sustained EPS improvement suggests better cost control or capital structure efficiency, supporting longer-term ability to fund operations and strategic initiatives.
Negative Factors
Sharp revenue decline
A near-55% revenue decline is a material structural headwind for scale, margin absorption and market positioning. Sustained top-line contraction limits reinvestment, increases per-unit costs and raises reliance on margin recovery or new product launches to restore durable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
EPS Growth
Reported EPS growth of ~26% indicates the company has improved per-share profitability despite top-line pressures. Sustained EPS improvement suggests better cost control or capital structure efficiency, supporting longer-term ability to fund operations and strategic initiatives.
Read all positive factors
Meilleure Health International Industry Group Limited (2327) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.04B
Dividend Yield2%
Average Volume (3M)3.52M
Price to Earnings (P/E)19.8
Beta (1Y)0.39
Revenue Growth-54.92%
EPS Growth26.32%
CountryHK
Employees46
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)<0.01
Shares Outstanding4,093,756,600
10 Day Avg. Volume6,054,000
30 Day Avg. Volume3,517,820
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)0.99
Price to Sales (P/S)23.42
P/FCF Ratio6.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Meilleure Health International Industry Group Limited Business Overview & Revenue Model
Company Description
Meilleure Health International Industry Group Limited, an investment holding company, engages in industrial hemp, healthcare-related, trading, agency service, property investment and leasing, and property development businesses in Hong Kong, the P...
How the Company Makes Money
Meilleure Health generates revenue through the sale of its health products, including dietary supplements and wellness solutions, both in domestic and international markets. The company employs a multi-channel distribution strategy that includes d...
Meilleure Health International Industry Group Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.10M | 50.68M | 129.30M | 119.89M | 253.03M | 265.13M |
| Gross Profit | 27.67M | 28.91M | 78.09M | 66.76M | 100.93M | 111.25M |
| EBITDA | 40.49M | 56.52M | 71.38M | 55.46M | 108.73M | 129.38M |
| Net Income | 39.17M | 32.48M | 40.83M | 17.82M | 60.32M | 83.44M |
Balance Sheet | ||||||
| Total Assets | 1.75B | 1.67B | 1.70B | 1.71B | 1.74B | 1.70B |
| Cash, Cash Equivalents and Short-Term Investments | 9.95M | 29.94M | 106.31M | 210.99M | 380.39M | 281.28M |
| Total Debt | 345.96M | 303.06M | 297.06M | 249.13M | 170.42M | 154.84M |
| Total Liabilities | 530.15M | 467.29M | 442.89M | 384.18M | 306.35M | 299.60M |
| Stockholders Equity | 1.22B | 1.20B | 1.25B | 1.32B | 1.43B | 1.40B |
Cash Flow | ||||||
| Free Cash Flow | 60.97M | 188.62M | -137.32M | 42.10M | -89.79M | 70.39M |
| Operating Cash Flow | 61.64M | 188.75M | -136.49M | 43.15M | -83.27M | 70.81M |
| Investing Cash Flow | -94.72M | -253.98M | 53.72M | -134.76M | 161.56M | 108.14M |
| Financing Cash Flow | 23.96M | -6.39M | -18.90M | 41.93M | -38.22M | -108.88M |
Meilleure Health International Industry Group Limited Technical Analysis
Positive
0.28
Price Trends
0.25
Positive
0.27
Negative
0.27
Negative
Market Momentum
<0.01
Negative
54.38
Neutral
126.47
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.25, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of 126.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2327.
Meilleure Health International Industry Group Limited Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | HK$423.00M | 14.86 | 37.44% | ― | -11.49% | 85.40% | |
52 Neutral | HK$1.06B | 0.33 | -194.26% | ― | -64.04% | 1.66% | |
51 Neutral | HK$1.04B | 19.78 | 3.24% | 2.00% | -54.92% | 26.32% | |
46 Neutral | HK$1.26B | 1.27 | -3.32% | 3.80% | 10.38% | 7.39% | |
44 Neutral | HK$397.85M | -6.11 | -12.32% | ― | -26.45% | 33.00% |
* Industrials Sector Average
HK:2327
Meilleure Health International Industry Group Limited
0.26
<0.01
2.41%
HK:0025
Chevalier International Holdings Limited
4.17
0.33
8.59%
HK:2322
Hong Kong ChaoShang Group Ltd.
0.09
-0.41
-82.00%
HK:0474
Aceso Life Science Group Limited
0.12
0.07
140.00%
HK:8162
Loco Hong Kong Holdings Ltd
0.43
-0.13
-22.73%
Meilleure Health International Industry Group Limited Corporate Events
Meilleure Health to Acquire Full Control of Jiangsu Yide in Connected Deal
Jan 8, 2026
Meilleure Health International Industry Group Limited has agreed to acquire the entire equity interest in Jiangsu Yide from U-Home Group and individual vendor Tan Wensheng for RMB124.77 million (about HK$137 million), in a deal that will make Jian...
Meilleure Health Appoints Joint Company Secretaries as Long-Serving Officer Resigns
Dec 31, 2025
Meilleure Health International Industry Group Limited has announced that its company secretary, Mr. Li Shu Pai, will resign with effect from 31 December 2025 to focus on personal commitments, with the board emphasizing that he departs without any ...
Meilleure Health Adds CEO and INED to Nomination Committee to Meet New HK Governance Rules
Dec 31, 2025
Meilleure Health International Industry Group Limited has appointed executive director and chief executive officer Ms. Zhou Wen Chuan and independent non-executive director Mr. Chen Shi as members of its nomination committee, effective 31 December...
Meilleure Health Outlines Board Composition and Committee Roles
Dec 31, 2025
Meilleure Health International Industry Group Limited has announced the current composition of its board of directors and the allocation of roles across its four key board committees. The Board is led by co-chairmen Mr. Zhou Xuzhou and Dr. Zeng We...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.